癌症疫苗取得重大突破！2020年八大实体肿瘤治疗性疫苗数据汇总
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_gif/CwkERAMhICyQPuwF83xnm1NfLsdtfoJ8UglT69n6pQj0NTCEkWpN45J5klFQnnoicwmA8X1CVew8sbEuBvd9uZg/640?wx_fmt=gif&tp=webp&wxfrom=5&wx_lazy=1" style="width: 50%; margin-bottom: 20px;"></a></p><span style="color: black;">除了免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂，过继性细胞免疫疗法之外，癌症疫苗是属于癌症免疫疗法中最新的一种治疗方式，<span style="color: black;">亦</span>是免疫治疗的第三张王牌。</span><span style="color: black;">与免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂和过继性细胞疗法不同，人类之<span style="color: black;">因此</span>寄<span style="color: black;">期盼</span>于疫苗来预防和<span style="color: black;">解决</span><span style="color: black;">包含</span>癌症在内的各类<span style="color: black;">疾患</span>，是<span style="color: black;">由于</span><span style="color: black;">没</span>论是用于预防传<span style="color: black;">患病</span>还是预防和治疗癌症，疫苗都<span style="color: black;">能够</span><span style="color: black;">经过</span>类似的机制发挥<span style="color: black;">功效</span>：</span><span style="color: black;"><strong style="color: blue;">它们<span style="color: black;">教诲</span>免疫系统将传染性病原体或癌细胞识别为<span style="color: black;">必须</span>消除的外来物质。癌细胞表面存在特殊的蛋白质，<span style="color: black;">经过</span>靶向这些蛋白质，免疫系统<span style="color: black;">能够</span>特异性地消除癌细胞，<span style="color: black;">同期</span>不<span style="color: black;">损伤</span>正常的细胞。</strong></span><span style="color: black;"><span style="color: black;">另外</span>，疫苗还能防止癌症复发，清除治疗后残留的癌细胞。在过去的30年中，<span style="color: black;">已然</span>在动物模型和人类中对癌症疫苗进行了广泛的<span style="color: black;">科研</span>，<span style="color: black;">触及</span>多种不同类型的癌症。</span>个体化癌症疫苗迎来井喷时代！<span style="color: black;">2020年，<span style="color: black;">全世界</span>癌症“ 治疗性疫苗 ” <span style="color: black;">开发</span>遍地开花，各类癌症的癌症疫苗纷纷<span style="color: black;">面世</span>，并取得了令人振奋的临床数据。</span><span style="color: black;">个体化癌</span><span style="color: black;">症疫苗迎来井喷时代！</span><span style="color: black;"><span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部为<span style="color: black;">大众</span>整理了今年非常值得期待的，在各大国际会议上取得惊艳数据的十大癌症疫苗，<span style="color: black;">期盼</span>给<span style="color: black;">大众</span>带来战胜癌症<span style="color: black;">自信心</span>。</span><span style="color: black;">想<span style="color: black;">认识</span>详情的<span style="color: black;">病人</span><span style="color: black;">能够</span>联系<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部。</span><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/CwkERAMhICywYa6VuM7mnsV07o9IAUxXllOueWwGIAzof3Jntc7fY9lV0WbjqvNl8BONV5wgYQGtzSY7QCrWJw/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></a><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">一，肺癌：</span><span style="color: black;">破解PD-1耐药，Tedopi疫苗震惊四座</span></p><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">2020年4月1日，OSE Immun</span><span style="color: black;">otherapeutics<span style="color: black;">机构</span>重磅宣布其新型抗癌疫苗Tedopi在非小细胞肺癌的Ⅲ期临床<span style="color: black;">实验</span>（代号为Atalante 1）取得了阳性结果，入组的所有<span style="color: black;">病人</span>在免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂（PD-1）耐药或失败后，二线或三线<span style="color: black;">运用</span>Tedopi疫苗，一年的总<span style="color: black;">存活</span>率达到46%，远超预设的25%！</span><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICzKJiaNgFKic3u5Lhczn40mmFWL3a1JiabBzXdK8H0zs1a5LEKPObLNEzyDuOnX63mA7SPzBaSExdpmw/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">一位54岁的晚期肺癌<span style="color: black;">病人</span>在经过5次的新型肺癌疫苗注射后，肿瘤就<span style="color: black;">快速</span>萎缩（从39毫米降至23毫米），截止<span style="color: black;">报告</span>时，<span style="color: black;">存活</span>期<span style="color: black;">已然</span>超过20.6个月，<span style="color: black;">日前</span>仍在随访中。原文链接：</span><a style="color: black;">重磅！新型肺癌疫苗Tedop</a>iⅢ期<span style="color: black;">实验</span>数据<span style="color: black;">颁布</span>，竟能破解PD-1耐药！<img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICzcibXCAwKpGeMg3nUbKAIUTwsIg9Ou6Gaf24NibVmDgfu7I0C6FxM6BdB8IU0Dy1WU3FvbbPNjdv3A/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">二，</span><span style="color: black;">乳腺癌：</span><span style="color: black;">VRP-HER2疫苗联合PD-1二期<span style="color: black;">科研</span><span style="color: black;">起步</span></span></p><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">杜克大学的Lyerly及其同事构建了一种疫苗，<span style="color: black;">运用</span>中性的病毒载体携带针对HER2蛋白的基因信息。一旦进入人体，疫苗就会瞄准癌细胞中的HER2蛋白，从而激发免疫系统对癌症发起攻击。VRP-HER2疫苗<span style="color: black;">能够</span><span style="color: black;">增多</span>HER2特异性记忆CD8 T细胞，并在临床前和临床<span style="color: black;">科研</span>中<span style="color: black;">拥有</span>抗肿瘤<span style="color: black;">功效</span>。</span><span style="color: black;"><span style="color: black;">日前</span>杜克大学的<span style="color: black;">科研</span>人员正在<span style="color: black;">起步</span>二期临床<span style="color: black;">实验</span>(NCT03632941)将VRP-HER2与PD-1（派姆单抗）结合，在晚期HER2+中进行<span style="color: black;">实验</span>。<span style="color: black;">倘若</span><span style="color: black;">大众</span>想进一步<span style="color: black;">认识</span><span style="color: black;">关联</span>的新药<span style="color: black;">实验</span>招募信息，<span style="color: black;">能够</span>致电<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部（400-666-7998）。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">三，结直肠癌：新型疫苗<span style="color: black;">PolyPEP</span><span style="color: black;">I1018</span>专门针对MSS型</p><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">在2020年ASCO大会上，美国梅奥诊所（美国US news最佳医院排名<span style="color: black;">第1</span>）报告了一款新型的结直肠癌疫苗<span style="color: black;">科研</span>数据非常振奋人心。</span><span style="color: black;">这项实验的代号为OBERTO，是在梅奥诊所进行的，<span style="color: black;">重点</span>的目的是<span style="color: black;">科研</span>将新型的癌症疫苗PolyPEPI1018疫用于一线化疗后<span style="color: black;">做为</span>转移性结直肠癌维持治疗的安全性和有效性<span style="color: black;">怎样</span>。值得一提的是，</span><span style="color: black;"><strong style="color: blue;">这款疫苗是专门针<span style="color: black;">针对</span>MSS型结直肠癌的。</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">结果<span style="color: black;">表示</span>：</span></strong></span><span style="color: black;">在11名接种疫苗的<span style="color: black;">病人</span>中，3名病情<span style="color: black;">发展</span>，5名病情稳定，3名<span style="color: black;">病人</span>部分肿瘤缓解，其中两名的肿瘤已缩小到<span style="color: black;">能够</span>接受手术的范围，更值得一提的是，其中一位<span style="color: black;">病人</span>在手术后的原发肿瘤中<span style="color: black;">发掘</span><span style="color: black;">已然</span><span style="color: black;">无</span>存活的肿瘤细胞，这说明，癌症疫苗<span style="color: black;">已然</span>将肿瘤细胞<span style="color: black;">所有</span>杀灭。<span style="color: black;">因此呢</span>，PolyPEPI1018可有效恢复<span style="color: black;">病人</span>的免疫反应。用PolyPEPI1018疫苗进行的治疗和维持治疗是安全的，并初步证明了疫苗对MSS mCRC肿瘤<span style="color: black;">拥有</span><span style="color: black;">初期</span>临床活性的证据，能够有效的延缓肿瘤<span style="color: black;">发展</span>。</span><img src="https://mmbiz.qpic.cn/mmbiz_jpg/CwkERAMhICy9C8mddQxiaF8uXTocpwmvK1iaghcicmXRFE6ckKVDvHz42Eic7NMfv1icFUeHwzJn3Oib1j2Dg1dECQyQ/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">这项结果另<span style="color: black;">科研</span>人员非常振奋。<span style="color: black;">科研</span>人员说，治疗是安全并且耐受良好，<span style="color: black;">无</span>严重的不良事件，并且所有<span style="color: black;">病人</span>均产生了源自PolyPEPI1018的免疫反应。</span><strong style="color: blue;"><span style="color: black;">一次注射PolyPEPI1018会<span style="color: black;">引起</span>“前所未有的免疫学活性”，每位<span style="color: black;">病人</span>的T细胞靶向多达5种癌症蛋白</span></strong><span style="color: black;">，PolyPEPI1018与维持疗法<span style="color: black;">协同</span><span style="color: black;">运用</span>时<span style="color: black;">能够</span>产生持久反应。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">四，<span style="color: black;">脑肿瘤</span>：<span style="color: black;">AV-GBM-1</span>疫苗<span style="color: black;">明显</span>延长<span style="color: black;">存活</span>期</p><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">2020年4月8日，新型树突细胞疗法</span><span style="color: black;">AV-GBM-1</span><span style="color: black;">的II期临床<span style="color: black;">实验</span>数据<span style="color: black;">颁布</span>，<span style="color: black;">科研</span><span style="color: black;">表示</span>此款新型疫苗对延长新诊断的胶质母细胞瘤<span style="color: black;">病人</span>的中期总体<span style="color: black;">存活</span>期展现出<span style="color: black;">极重</span>的<span style="color: black;">潜能</span>。</span><span style="color: black;">在接受AV-GBM-1治疗的50例可<span style="color: black;">评定</span><span style="color: black;">病人</span>的15个月的总<span style="color: black;">存活</span>率为76%，而对照组的287例接受标准治疗的<span style="color: black;">病人</span>的12个月和15个月的总<span style="color: black;">存活</span>率分别为61%和48%。这<span style="color: black;">显示</span>，</span><span style="color: black;"><strong style="color: blue;">接受AV-GBM-1治疗的<span style="color: black;">病人</span>15个月的总<span style="color: black;">存活</span>率<span style="color: black;">加强</span>了28%，疗效格外<span style="color: black;">明显</span>。</strong></span><span style="color: black;">AV-GBM-1是一种<span style="color: black;">病人</span>自体的特异性树突状细胞疫苗，旨在利用<span style="color: black;">病人</span><span style="color: black;">自己</span>的免疫系统来寻找并消灭癌细胞这种树突细胞疫苗能够携带术后肿瘤组织中提取的特定抗原信息，注射后，将抗原信息传递给T细胞，激发起杀瘤活性。针对<span style="color: black;">病人</span>的自体疫苗虽然在<span style="color: black;">规律</span>上很<span style="color: black;">繁杂</span>，<span style="color: black;">然则</span>是一种可行的<span style="color: black;">办法</span>，能够与替莫唑胺和放射治疗<span style="color: black;">同期</span>进行；<span style="color: black;">亦</span><span style="color: black;">能够</span>从化疗和放疗中恢复后再注射AV-GBM-1疫苗。<span style="color: black;">病人</span><span style="color: black;">倘若</span>能够成功进行单科白细胞收集，则年龄在70岁以下都有资格参加<span style="color: black;">科研</span>。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxW4kKcZGfqhA0sg3KEnGEZzP3pelXltO7KVqINLWtNIwpab4iaibBqrldwodeBIVnYtpibPyibfbia4WQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">这种疗法理论上适用于所有的实体肿瘤，<span style="color: black;">因此呢</span>除胶质母细胞瘤外，Aivita Biomedical<span style="color: black;">机构</span>还正在进行其他2种AV-GBM-1在其他肿瘤类型中的临床<span style="color: black;">实验</span>。一项开放性单臂Ib期<span style="color: black;">实验</span>正在<span style="color: black;">评定</span>AV-GBM-1联合PD-1<span style="color: black;">控制</span>剂在转移性黑色素瘤<span style="color: black;">病人</span>中的安全性和有效性。此<span style="color: black;">实验</span>的征募工作尚未<span style="color: black;">起始</span>（NCT03743298）。</p>
</span><span style="color: black;">另一项正在招募卵巢癌<span style="color: black;">病人</span>的<span style="color: black;">实验</span>是一项双盲II期<span style="color: black;">科研</span>，<span style="color: black;">目的</span>纳入了99例<span style="color: black;">病人</span>（NCT02033616）。该<span style="color: black;">实验</span>以2：1的比例将<span style="color: black;">病人</span>与AV-GBM-1或自体单核细胞<span style="color: black;">做为</span>对照。</span><img src="https://mmbiz.qpic.cn/mmbiz_jpg/LghKSGmMJfLibo6NzmEmHPFmszbV86jOUUoUgFxFkWh479umicky54YYFqWkIibibAqCtStCU77o0PQJ689F2VJwBA/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">五，肾癌：完全缓解率翻倍！<span style="color: black;">ilixadencel进军一线治疗</span></p><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">在近期举行的2020年ASCO临床免疫肿瘤学研讨会上，一款新型疫苗的数据让医学家们为之振奋。</span><span style="color: black;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">ilixadencel（伊利沙定）中的活性<span style="color: black;">成份</span>是活化的同种异体树突状细胞，其实<span style="color: black;">便是</span>健康人血液中提取的树突细胞。这些细胞在体外被激活，能够产生<span style="color: black;">海量</span>有针对性的免疫刺激因子，制备成疫苗，直接注射在<span style="color: black;">病人</span>的肿瘤部位。疫苗在进入<span style="color: black;">身体</span>后相当于是免疫触发剂，可<span style="color: black;">诱发</span>肿瘤部位炎症反应，<span style="color: black;">从而</span>破坏肿瘤细胞和肿瘤组织，<span style="color: black;">同期</span>激活<span style="color: black;">病人</span><span style="color: black;">自己</span>的免疫细胞，<span style="color: black;">起步</span><span style="color: black;">病人</span><span style="color: black;">自己</span>对肿瘤的免疫过程。</p>
</span><span style="color: black;">1</span><span style="color: black;">有效率翻倍，新型树突细胞疫苗ilixadencel进军肾癌一线治疗</span><span style="color: black;"><span style="color: black;">截止</span>2019年12月，88例<span style="color: black;">病人</span>中<span style="color: black;">最后</span>有70例<span style="color: black;">病人</span>可<span style="color: black;">评定</span>，</span><span style="color: black;">结果<span style="color: black;">表示</span>：</span><span style="color: black;">完全缓解率（CR）：11%vs4%。ilixadencel联合治疗组中有5名完全缓解者（11％），随访30-33个月时，<span style="color: black;">她们</span><span style="color: black;">所有</span>还活着。而在仅接受舒尼替尼的对照组中，仅有一名完全缓解者（4％），但在41个月后死亡。</span><span style="color: black;">总<span style="color: black;">存活</span>率（OS)：54%vs37%。ilixadencel联合治疗组的总<span style="color: black;">存活</span>率为54％，而舒尼替尼单药治疗组为37％；</span><span style="color: black;">客观缓解率（ORR）：42%vs24%。ilixadencel联合治疗组客观缓解率为42％，而舒尼替尼组仅为24％，将近翻了一倍；</span><span style="color: black;">反应<span style="color: black;">连续</span>时间（DOR）：7.1个月vs2.9个月。ilixadencel<span style="color: black;">连续</span>中位反应时间为7.1个月，舒尼替尼仅为2.9个月，将近延长了3倍；</span><span style="color: black;">中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期分别为11.8个月11.0个月。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICzvstRgsZFqt2QAh53DElAgicwxtOlibicNx9hd39sEujauYTKcLkLdGR9U800D0bp26qhKuYOqvS0cQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><span style="color: black;">能够</span>看出，ilixadencel联合舒尼替尼一线治疗晚期肾癌，<span style="color: black;">能够</span>大大<span style="color: black;">加强</span>治疗的有效率，<span style="color: black;">病人</span>的总<span style="color: black;">存活</span>率和完全缓解率，并且更加安全。这款新型的疫苗<span style="color: black;">潜能</span><span style="color: black;">没</span>限，可用于治疗肝细胞癌，胃肠道间质瘤等实体肿瘤，<span style="color: black;">咱们</span>期待进一步的临床数据，<span style="color: black;">期盼</span>这款疫苗能<span style="color: black;">早点</span>上市造福<span style="color: black;">病人</span>。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">六，卵巢癌：<span style="color: black;">两年<span style="color: black;">存活</span>率100%！</span><span style="color: black;">OCDC疫苗前景<span style="color: black;">没</span>限</span></p><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">来自宾夕法尼亚大学佩雷尔曼医学院和宾夕法尼亚大学艾布拉姆森癌症中心的<span style="color: black;">科研</span>小组则尝试采用氧化自体全肿瘤细胞裂解物（OCDC）形成的自体树突状细胞进行免疫治疗。</span><span style="color: black;"><span style="color: black;">科研</span>人员抽取了晚期卵巢癌<span style="color: black;">病人</span>的外周血，筛选出合适的免疫细胞后将其培养成<span style="color: black;">海量</span>的树突状细胞。</span><span style="color: black;">（树突状细胞能摄取感染性病原体、肿瘤细胞或其他“异己”物质，并将其摄取的碎片重新<span style="color: black;">供给</span>给T细胞和其他免疫细胞，以<span style="color: black;">诱发</span>特定的免疫反应。</span><span style="color: black;">）</span><img src="https://mmbiz.qpic.cn/mmbiz_jpg/pHzHVM2oJO0PmUF9TzAe8dIqBa583l5WQZw8YwmHeo7exSel561mPYr5ENYonZng71ZatPAJfGVYt2Gr1ia49aQ/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><span style="color: black;">科研</span>人员将晚期卵巢癌<span style="color: black;">病人</span>外周血培育出的树突状细胞暴露在<span style="color: black;">病人</span>的肿瘤提取物中，并用干扰素γ激活细胞。最后将这些<span style="color: black;">持有</span>肿瘤细胞“碎片”或标识的树突状细胞重新注射会<span style="color: black;">病人</span><span style="color: black;">身体</span>，激活并<span style="color: black;">加强</span><span style="color: black;">病人</span><span style="color: black;">身体</span>的T细胞，<span style="color: black;">导致</span>对肿瘤细胞的免疫反应。</span><span style="color: black;">在<span style="color: black;">哪些</span>对其重输回<span style="color: black;">身体</span>的树突状细胞有所应答的<span style="color: black;">病人</span>中，晚期卵巢癌<span style="color: black;">病人</span>的2年总<span style="color: black;">存活</span>率达到了100%！</span><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">七，头颈癌：<span style="color: black;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率90%！mRNA-4157疫苗曙光初现</span></p><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">mRNA-4157疫苗是美国Moderna<span style="color: black;">机构</span><span style="color: black;">开发</span>的一款mRNA疫苗，<span style="color: black;">运用</span>一种新颖的基于基因的技术，<span style="color: black;">经过</span>将<span style="color: black;">病人</span>的正常细胞DNA序列与肿瘤的正常DNA序列进行比较，并确定肿瘤对DNA的特异性变化。<span style="color: black;">经过</span>与pembrolizumab（一种PD-1）结合<span style="color: black;">运用</span>，<span style="color: black;">科研</span>人员推测该疫苗<span style="color: black;">能够</span><span style="color: black;">诱发</span>免疫系统，使其对PD-1<span style="color: black;">控制</span>剂的反应更加灵敏，并降低癌症复发的<span style="color: black;">危害</span>。</p>
</span><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxf2X7n7yPrKCtzNicVIdf0zichhtUibBolUicPvm4d7HWiavc0m8UiaRhtqYyYvpdKrGicSvTcv3d0N2r9g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">2020年11月11日，Moderna<span style="color: black;">机构</span><span style="color: black;">颁布</span>了最新的代号为KEYNOTE-603的临床<span style="color: black;">实验</span>数据，再次证实mRNA-4157联合Keytruda能够缩小多种晚期实体肿瘤</span><span style="color: black;">病灶。</span><span style="color: black;">在10例HPV阴性的头颈部鳞状细胞癌<span style="color: black;">病人</span>中，总缓解率为50％：2完全缓解和3部分缓解。<span style="color: black;">同期</span>，4名<span style="color: black;">病人</span><span style="color: black;">疾患</span>稳定，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率（DCR）达到90%。</span><span style="color: black;">与单独<span style="color: black;">运用</span>PD-1<span style="color: black;">控制</span>剂相比，它<span style="color: black;">拥有</span><span style="color: black;">显著</span>的<span style="color: black;">优良</span>：中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期（mPFS）为9.8个月。</span><span style="color: black;">即使与Keytruda / chemo组合（一线治疗的标准护理）相比，结果<span style="color: black;">亦</span>令人满意，该组合产生的ORR为36％，mPFS为4.9个月。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">八，胰腺癌：<span style="color: black;">GVAX</span>疫苗攻击“癌王”</p><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICxib3IYibkwo0kLKdeicsYicRQHicDa4M0kCBcowIxjIkMxsolgEJSfib1AQXicKop8MWQo2ia2yEtQMYzH5g/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><span style="color: black;">科研</span>人员正在<span style="color: black;">科研</span>几种旨在<span style="color: black;">加强</span>免疫系统对胰腺癌细胞反应的治疗疫苗，<span style="color: black;">科研</span>的<span style="color: black;">重点</span>靶</span><span style="color: black;">点为MUC1，CEA,MESO等，这些疫苗单独或联合免疫<span style="color: black;">药品</span>进行<span style="color: black;">运用</span>。</span><span style="color: black;"><span style="color: black;">日前</span>在约翰·霍普金斯·金梅尔癌症中心正在进行一项联合或部联合PD-1阻断抗体（Nivolumab）和CD137激动剂抗体（Urelumab）的GM-CSF分泌同种异体胰腺癌疫苗的随机<span style="color: black;">科研</span>，用于新辅助和辅助治疗可手术切除的胰腺腺癌<span style="color: black;">病人</span>。</span>2020年肿瘤疫苗重磅<span style="color: black;">科研</span><span style="color: black;">发展</span>盘点<span style="color: black;">上文中已的癌症疫苗，</span><span style="color: black;">大部分<span style="color: black;">日前</span>都<span style="color: black;">处在</span><span style="color: black;">初期</span>的临床<span style="color: black;">实验</span><span style="color: black;">周期</span>，想接受治疗<span style="color: black;">仅有</span><span style="color: black;">经过</span>申请临床<span style="color: black;">实验</span>入组，像Tedopi疫苗<span style="color: black;">已然</span>进入到三期临床<span style="color: black;">实验</span>，有望上市，<span style="color: black;">咱们</span>期待能够看到<span style="color: black;">更加多</span>的有效数据。</span>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">另外</span>，还有<span style="color: black;">有些</span>国家的树突细胞疫苗<span style="color: black;">已然</span>正式进入临床应用，<span style="color: black;">有些</span><span style="color: black;">初期</span>肿瘤<span style="color: black;">病人</span><span style="color: black;">能够</span>在手术后<span style="color: black;">思虑</span><span style="color: black;">运用</span>疫苗联合放化疗辅助治疗，起到杀伤残余癌细胞，产生免疫记忆，预防癌症复发和转移。</span></p><span style="color: black;"><span style="color: black;">大众</span>可<span style="color: black;">经过</span><span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部<span style="color: black;">评定</span>申请。<span style="color: black;">另外</span>，<span style="color: black;">全世界</span>在研的抗癌疫苗临床<span style="color: black;">实验</span>有200多项，<span style="color: black;">大众</span><span style="color: black;">能够</span>添加文末二维码或致电，<span style="color: black;">经过</span>医学部匹配适合自己的抗癌疫苗临床<span style="color: black;">实验</span>。<span style="color: black;">”<span style="color: black;">专家</span>们说。“<span style="color: black;">倘若</span>成功，在随后的<span style="color: black;">实验</span>中，个体化疫苗将被用于各类癌症，<span style="color: black;">持有</span>足够数量的新抗原接种疫苗<span style="color: black;">拥有</span>巨大<span style="color: black;">潜能</span>。</span></span><span style="color: black;"><span style="color: black;">以下是<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部整理的2020年肿瘤疫苗重磅<span style="color: black;">发展</span><span style="color: black;">文案</span>，<span style="color: black;">大众</span><span style="color: black;">能够</span><span style="color: black;">保藏</span>：</span></span><a style="color: black;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率高达90%！新型癌症疫苗mRNA-4157对多种实体瘤有效</a><a style="color: black;">《nature》子刊：100%存活！对实体瘤有效的癌症疫苗初步<span style="color: black;">开发</span>成功！</a><a style="color: black;">通用型肿瘤疫苗横空出世！三分之一肺癌<span style="color: black;">病人</span><span style="color: black;">存活</span>期超过5年！</a><a style="color: black;">又一款免疫王炸组合诞生！癌症疫苗联合PD-L1对多种肿瘤有效</a><a style="color: black;">News！预防复发</a>的新型癌症疫苗获初步有效认定，将开启Ⅱ期<span style="color: black;">实验</span><a style="color: black;">癌症疫苗取得重大突破！针对血液和实体瘤的通用型疫苗即将进入人体<span style="color: black;">实验</span></a><a style="color: black;">85%MSS型结直肠癌<span style="color: black;">病人</span>长<span style="color: black;">存活</span>的新<span style="color: black;">期盼</span>！新型疫苗PolyPEPI1018横空出世！</a><a style="color: black;">覆盖八大癌症！新型癌症疫苗<span style="color: black;">作为</span>免疫治疗的第三张“王牌”</a><a style="color: black;">2020乳腺癌靶向，免疫，疫苗最新<span style="color: black;">科研</span><span style="color: black;">发展</span>盘点</a><a style="color: black;">激活自</a>身的免疫系统清除癌细胞！树突细胞疫苗在实体肿瘤中的最新<span style="color: black;">科研</span><span style="color: black;">发展</span>一览<a style="color: black;">2020实体肿瘤癌症疫苗最新数据汇总（覆盖八大肿瘤）</a><a style="color: black;">疫苗真的<span style="color: black;">能够</span>预防和治疗癌症吗？这十个真相要<span style="color: black;">认识</span></a><a style="color: black;">完全缓解率大幅<span style="color: black;">提高</span>！新型癌症疫苗前景<span style="color: black;">没</span>限！</a><a style="color: black;">五年<span style="color: black;">存活</span>率不到20%！她用这款癌症疫苗救了自己，如今已<span style="color: black;">没</span>癌16年！</a><a style="color: black;">重磅！新型肺癌疫苗Tedop</a>iⅢ期<span style="color: black;">实验</span>数据<span style="color: black;">颁布</span>，竟能破解PD-1耐药！<a style="color: black;">王炸组合！2年总<span style="color: black;">存活</span>率达100%，个性化抗癌疫苗再获突破！</a><a style="color: black;"><span style="color: black;">将来</span>十年，<span style="color: black;">青春</span>人的结直肠癌发病率将超过90％，更致命！预防性疫苗已<span style="color: black;">面世</span>！</a><a style="color: black;"><span style="color: black;">贡献卓越！古巴已为全人类<span style="color: black;">开发</span>出四种对抗癌症的疫苗！</span></a>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">扫描添加病友群</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">最新<span style="color: black;">新闻</span>｜新技术｜新药<span style="color: black;">开发</span>｜权威专家</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">入群免费领取抗癌资料</p><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfKPeOCbx2LAzDww3AR9aHstzvgc7bHJjGSR89UNujUAicSmf36kZgmy2yZgibw5cvQqdhSQPib9W6LNA/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/LghKSGmMJfKPeOCbx2LAzDww3AR9aHstF1tmKS9dJ2TEspRuuLrTnHzade85ylL4glhS4icIuIa6lTQxYicLsT5A/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">扫描二维码</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">备注病种添加群主</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">各大药厂及临床</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">招募平台<span style="color: black;">媒介</span>合作</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/CwkERAMhICz0mF2LKMxePBxevCWPzJ0RHW9jwSWzWN0EibHOVhRM2bDJ1MqtcP2b0aXmYDriakaxbWnFhDwnbkKw/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></strong></p><span style="color: black;"><strong style="color: blue;">癌症<span style="color: black;">归类</span><span style="color: black;">文案</span></strong>：</span><span style="color: black;">·<a style="color: black;">肺癌</a> ·<a style="color: black;">胃癌</a> ·<a style="color: black;">结直肠癌</a> ·<a style="color: black;">肝癌</a> ·<a style="color: black;">胰腺癌</a> ·<a style="color: black;">乳腺癌</a> ·<a style="color: black;">肉瘤</a> ·<a style="color: black;">儿童肿瘤</a> <span style="color: black;">·<a style="color: black;">妇科肿瘤</a> ·<a style="color: black;">泌尿系统肿瘤</a> ·<a style="color: black;">其他肿瘤</a></span></span><span style="color: black;"> <strong style="color: blue;">癌症技术<span style="color: black;">：</span></strong></span><span style="color: black;"><span style="color: black;"> ·<a style="color: black;">PD-1 </a> ·<a style="color: black;">基因检测</a> ·<a style="color: black;">靶向治疗</a> </span><span style="color: black;">·<a style="color: black;">质子治疗</a> ·<a style="color: black;">免疫治疗</a> ·<a style="color: black;">电场治疗</a> ·<a style="color: black;">专家会诊</a> ·<a style="color: black;">出国<span style="color: black;">看病</span></a></span></span>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/CwkERAMhICyQPuwF83xnm1NfLsdtfoJ8KjCUZDFfYP2MRJl2cUXkp9DhFFicuMribzZJ2Cbq03J2zbfPyP7MYbwQ/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/CwkERAMhICw6w1OxVKwmcntutE03ibTKS199bVH79YTeHib4wKnWno0wicVS2A85I6OwHaPJfjTJI0qIFmb3sib6bA/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
我深感你的理解与共鸣，愿对话长流。 外链发布论坛学习网络优化SEO。 楼主的文章非常有意义，提升了我的知识水平。 回顾过去一年，是艰难的一年；展望未来，是辉煌的一年。
页:
[1]